Next Article in Journal
Thrombophilia and Pregnancy Complications
Next Article in Special Issue
Synthesis and Evaluation of Neuroprotective Selenoflavanones
Previous Article in Journal
Neuropeptide Trefoil Factor 3 Reverses Depressive-Like Behaviors by Activation of BDNF-ERK-CREB Signaling in Olfactory Bulbectomized Rats
Previous Article in Special Issue
Myricetin Attenuates Depressant-Like Behavior in Mice Subjected to Repeated Restraint Stress
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(12), 28401-28417; doi:10.3390/ijms161226099

Cytidine 5′-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives

1
IRCCS-Fondazione GB Bietti, Via Livenza, 3, 00198 Rome, Italy
2
DSMC, Università degli studi di Brescia, USVD “Centro per lo studio del Glaucoma” P.le Spedali Civili, 1, 25123 Brescia, Italy
3
DSCMT, Università di Roma Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
*
Authors to whom correspondence should be addressed.
Academic Editor: Katalin Prokai-Tatrai
Received: 31 October 2015 / Revised: 17 November 2015 / Accepted: 19 November 2015 / Published: 30 November 2015
(This article belongs to the Collection Neuroprotective Strategies)
View Full-Text   |   Download PDF [561 KB, uploaded 30 November 2015]   |  

Abstract

Cytidine 5′-diphosphocholine or citicoline is an endogenous compound that acts in the biosynthetic pathway of phospholipids of cell membranes, particularly phosphatidylcholine, and it is able to increase neurotrasmitters levels in the central nervous system. Citicoline has shown positive effects in Parkinson’s disease and Alzheimer’s disease, as well as in amblyopia. Glaucoma is a neurodegenerative disease currently considered a disease involving ocular and visual brain structures. Neuroprotection has been proposed as a valid therapeutic option for those patients progressing despite a well-controlled intraocular pressure, the main risk factor for the progression of the disease. The aim of this review is to critically summarize the current evidence about the effect of citicoline in glaucoma. View Full-Text
Keywords: citicoline; glaucoma; neuroprotection; retinal ganglion cells citicoline; glaucoma; neuroprotection; retinal ganglion cells
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Roberti, G.; Tanga, L.; Michelessi, M.; Quaranta, L.; Parisi, V.; Manni, G.; Oddone, F. Cytidine 5′-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives. Int. J. Mol. Sci. 2015, 16, 28401-28417.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top